Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 6/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | HMOX2 | P30519 | 1/20 | 0.43 |
| ▸ | CRYZ | Q08257 | 1/20 | 0.43 |
| ▸ | VAT1 | Q99536 | 1/20 | 0.43 |
| ▸ | RTN4 | Q9NQC3 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | BCL2A1 | Q16548 | 4/20 | 0.37 |
| ▸ | FAAH | O00519 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | BID | P55957 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16636983 | 0.84 | KRAS (0.61) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL29765668 | 0.84 | KRAS (0.61) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL23565220 | 0.77 | KRAS (0.64) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL29766036 | 0.76 | KRAS (0.58) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL29765950 | 0.76 | KRAS (0.70) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL16636888 | 0.76 | KRAS (0.58) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL16647016 | 0.76 | KRAS (0.70) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL29654141 | 0.74 | KRAS (0.48) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL29517664 | 0.73 | KRAS (0.48) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL20296659 | 0.73 | KRAS (0.48) | KRASEGFRHMOX2CRYZVAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10111874-B2 | Combination therapies for treatment of cancer | ARAXES PHARMA LLC (US) | 2018-10-30 | — | — | US | disclosed |
| US-20160166571-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | ARAXES PHARMA LLC | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10111874-B2 | Combination therapies for treatment of cancer | KRAS, TP53, HRAS | KRAS 1/4885EGFR 16/4885HMOX2 2281/4885 |
| US-20160166571-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | KRAS, TP53, HRAS | KRAS 1/4885EGFR 16/4885HMOX2 2281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.